A small study has found that no Covid-19 mRNA vaccine is present in human breastmilk following vaccination. The study by University of California San Francisco researchers provides early evidence that the vaccine mRNA is not transferred to the infant via breastmilk.
The study analysed the breastmilk of seven women after they received the Pfizer and Moderna mRNA vaccines and found no trace of the vaccine. The findings, although from a small sample, offer the first direct data of vaccine safety during breastfeeding and could allay concerns among those who have declined vaccination or discontinued breastfeeding due to concern that vaccination might alter human milk. The paper appears in JAMA Pediatrics.
The World Health Organization recommends people should continue breastfeeding following vaccination for Covid-19.
The Academy of Breastfeeding Medicine has said there is little risk of vaccine mRNA entering breast tissue or being transferred to milk, which theoretically could affect infant immunity.
“The results strengthen current recommendations that the mRNA vaccines are safe in lactation, and that lactating individuals who receive the Covid vaccine should not stop breastfeeding,” said corresponding author Stephanie L. Gaw, MD, PhD, assistant professor of Maternal-Fetal Medicine at UCSF.
The study was conducted from December 2020 to February 2021. The mothers’ mean age was 37.8 years and their children ranged in age from one month to three years. Milk samples were collected prior to vaccination and at various times up to 48 hours after vaccination.
Researchers found that none of the samples showed detectable levels of vaccine mRNA in any component of the milk.
The authors noted that the study was limited by the small sample size and said that further clinical data from larger populations was needed to better estimate the effect of the vaccines on lactation outcomes.
Reference
Golan Y, Prahl M, Cassidy A, et al. Evaluation of Messenger RNA From Covid-19 BTN162b2 and mRNA-1273 Vaccines in Human Milk. JAMA Pediatr. Published online July 06, 2021.
https://doi.org/10.1001/jamapediatrics.2021.1929
FDA clears Dexcom real-time diabetes monitoring APIs for third-party Apps and devices
, /in Product News /by panglobalDexCom, a global leader in real-time continuous glucose monitoring for people with diabetes, has received US FDA clearance of the Dexcom Partner Web APIs, enabling invited third-party developers to integrate real-time CGM data into their digital health apps and devices.
“The new APIs will help seamlessly integrate the power of real-time Dexcom CGM data into some of the leading diabetes and digital health solutions,” explained Jake Leach, chief technology officer at Dexcom
“FDA clearance of our real-time APIs further solidifies Dexcom as the leader in interoperable CGM, giving Dexcom users even more choice in how they view and interact with their glucose data,” said Leach.
People with diabetes and their healthcare providers will benefit from the integration of real-time Dexcom CGM data into third-party apps and devices in a multitude of ways. For example, it will:
Garmin, Teladoc Health
Several prominent diabetes and digital health companies have been invited to access the real-time APIs and are already in the testing and development phase, including Garmin and Teladoc Health’s Livongo for Diabetes.
Joe Schrick, vice president of fitness at Garmin, said: “Garmin welcomes the opportunity to bring Dexcom CGM data to runners, cyclists and everyday users who rely on the technology 24/7 to proactively manage their diabetes. We are proud to be part of this integration that will allow users a secondary way to quickly and discreetly view estimated glucose levels and trends right from their smartwatch at any time.”
Study finds no Covid-19 mRNA vaccine in breast milk
, /in Corona News, E-News /by panglobalA small study has found that no Covid-19 mRNA vaccine is present in human breastmilk following vaccination. The study by University of California San Francisco researchers provides early evidence that the vaccine mRNA is not transferred to the infant via breastmilk.
The study analysed the breastmilk of seven women after they received the Pfizer and Moderna mRNA vaccines and found no trace of the vaccine. The findings, although from a small sample, offer the first direct data of vaccine safety during breastfeeding and could allay concerns among those who have declined vaccination or discontinued breastfeeding due to concern that vaccination might alter human milk. The paper appears in JAMA Pediatrics.
The World Health Organization recommends people should continue breastfeeding following vaccination for Covid-19.
The Academy of Breastfeeding Medicine has said there is little risk of vaccine mRNA entering breast tissue or being transferred to milk, which theoretically could affect infant immunity.
“The results strengthen current recommendations that the mRNA vaccines are safe in lactation, and that lactating individuals who receive the Covid vaccine should not stop breastfeeding,” said corresponding author Stephanie L. Gaw, MD, PhD, assistant professor of Maternal-Fetal Medicine at UCSF.
The study was conducted from December 2020 to February 2021. The mothers’ mean age was 37.8 years and their children ranged in age from one month to three years. Milk samples were collected prior to vaccination and at various times up to 48 hours after vaccination.
Researchers found that none of the samples showed detectable levels of vaccine mRNA in any component of the milk.
The authors noted that the study was limited by the small sample size and said that further clinical data from larger populations was needed to better estimate the effect of the vaccines on lactation outcomes.
Reference
Golan Y, Prahl M, Cassidy A, et al. Evaluation of Messenger RNA From Covid-19 BTN162b2 and mRNA-1273 Vaccines in Human Milk. JAMA Pediatr. Published online July 06, 2021.
https://doi.org/10.1001/jamapediatrics.2021.1929
First-ever systemically administered CRISPR therapy paves way for revolution in treatment of genetic disorders
, /in Featured Articles /by panglobalIntellia Therapeutics and Regeneron Pharmaceuticals have presented positive interim data from an ongoing Phase 1 clinical study of their lead in vivo genome editing candidate, NTLA-2001, which is being developed as a single-dose treatment for transthyretin (ATTR) amyloidosis.
Financing smart buildings – delivering value in the “new normal”
, /in Featured Articles /by panglobalCOVID-19 has caused a crisis for building owners and landlords – both in the public and private sectors. Patterns of work and public service are clearly changing as a result of the crisis and its aftermath.
Aidence, ScreenPoint Medical and Thirona launch video series explaining medical imaging AI
, /in Featured Articles /by panglobalThree leading AI scale-ups – Aidence, ScreenPoint Medical and Thirona – have launched an informative video series “Opening the black box of AI in medical imaging”. Their aim is to close knowledge gaps and increase trust in imaging AI by explaining how this emerging technology can be applied in radiology. The collaboration is unique in […]
NDD updates EasyOne product range to be compliant with ATS/ERS spirometry standard
, /in Product News /by panglobalNDD Medical Technologies (NDD), a leading provider of diagnostic technology enabling healthcare professionals the early detection of COPD and other chronic lung diseases, has updated the entire EasyOne® product range, including the EasyOne Air, Easy on-PC, EasyOne Pro, and EasyOne Pro LAB, to be compliant with the ATS/ERS Standardization of Spirometry 2019.
Siemens Healthineers launches Somatom X.ceed CT with bundled AI companions for fast, precise interventions
, /in Featured Articles /by Siemens HealthineersSiemens Healthineers has unveiled its fastest single-source CT scanner – Somatom X.ceed – a high-resolution, high-speed, low-dose CT scanner, which the company says is engineered specifically for the most challenging clinical areas where time and precision are of essence.
Nova POC creatinine/eGFR method more accurate than laboratory method: large medical centre study shows
, /in Product News /by panglobalIn a 670-patient study funded by the International Society of Nephrology, the South Africa Medical Research Council, and the University of Witwatersrand, Johannesburg, South Africa, the Nova POC StatSensor Creatinine/ eGFR meter was more accurate than the central laboratory IDMS-traceable Jaffe methodology in estimating GFR when both methods were compared to measured GFR (mGFR).
GE Healthcare’s AIR Recon DL receives FDA clearance on SIGNA 7.0T
, /in Featured Articles /by GE Healthcare GmbHGE Healthcare’s AIR Recon DL, the industry’s first deep learning image reconstruction technology that works across all anatomies, is now FDA 510(k) cleared on SIGNA 7.0T magnetic resonance imaging (MRI) scanners – the world’s most advanced FDA-cleared MRI device.
Cognoa’s autism spectrum disorder diagnosis aid approved by US FDA
, /in Product News /by panglobalThe U.S. FDA has authorized marketing of a device to help diagnose autism spectrum disorder (ASD). The Cognoa ASD Diagnosis Aid is a machine learning-based software intended to help healthcare providers diagnose ASD in children 18 months through 5 years of age who exhibit potential symptoms of the disorder.